An open-label phase 2 study to evaluate the safety and efficacy of CCX168 in subjects with IgA Nephropathy on stable RAAS blockade.
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Avacopan (Primary)
- Indications IgA nephropathy
- Focus Adverse reactions; Proof of concept
- Sponsors ChemoCentryx
- 06 Jun 2017 Results presented at the 54th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress 2017, according to a ChemoCentryx Inc. media release.
- 06 Jun 2017 Results published in a ChemoCentryx Inc. media release.
- 19 Dec 2016 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History